

Supplementary Files

Supplementary File S1: Overview of queries for patient inclusion and data extraction in CTcue. (See separate excel file).

Supplementary File S2: Treatment limiting adverse events per individual patient for nivolumab (2a), pembrolizumab (2b), and dabrafenib plus trametinib (2c).

Supplementary file 2a										
Nivolumab N = 9										
Treatment-limiting adverse event per individual patient	1	2	3	4	5	6	7	8	9	Total
Colitis	1	1								2
Pneumonitis		1	1							2
Hepatitis				1	1					2
Thyroiditis				1	1					2
Myalgia				1						1
Myocarditis				1						1
Arthralgia						1				1
Hypocortisolism							1			1
Polymyalgia rheumatica								1		1
Meningitis									1	1
Adrenalitis									1	1
Total	1	2	1	4	2	1	1	1	2	

Supplementary file 2b	
Pembrolizumab N = 3	
Treatment-limiting adverse event per individual patient	Total
Colitis	1
Arthralgia	1
Myalgia	1
Pneumonitis	1
Total	1 2 1

Supplementary file 2c										
Dabrafenib plus trametinib N = 8										
Treatment-limiting adverse event per individual patient	1	2	3	4	5	6	7	8		Total
Pyrexia	1	1	1	1	-	-	1	-		5
Chills	1	1	1	-	-	-	-	-		3
Nausea	1	1	1	-	-	-	-	-		3
Myalgia	1	-	-	-	-	1	-	-		2
Headache	1	-	-	-	-	-	-	-		1
Liver function disorders	1	-	-	-	-	-	-	-		1
Fatigue	-	1	-	-	-	-	-	1		2
Syncope	-	1	-	-	-	-	-	-		1
Skin disorder	-	-	-	1	1	1	1	-		4
Allergic reaction	-	-	-	-	1	-	-	-		1
Tachycardia	-	-	-	-	1	-	-	-		1
Decreased appetite	-	-	1	-	-	-	-	-		1
Arthralgia	-	-	-	-	-	1	-	-		1
Malaise	-	-	-	1	-	-	-	1		2
Total	6	5	4	3	3	3	2	2		